ARISTADA®
(aripiprazole lauroxil)
ARISTADA INITIO®
(aripiprazole lauroxil)
Publications
Studies designed, executed, and funded by Alkermes Inc.
Aug 2015
A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia
The Journal of Clinical Psychiatry
AUTHOR(S)
Aug 2017
Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia
The Journal of Clinical Psychiatry
AUTHOR(S)
Aug 2019
Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia
CNS Spectrums
AUTHOR(S)
Apr 2020
Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study
The Journal of Clinical Psychiatry
AUTHOR(S)
Jul 2020
Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study
The Journal of Clinical Psychiatry
AUTHOR(S)
May 2022
Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals
CNS Spectrums
AUTHOR(S)
Mar 2025
Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia
Neuropsychiatric Disease and Treatment
AUTHOR(S)
